Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opus Genetics ( (IRD) ) has provided an announcement.
On April 1, 2026, Opus Genetics, Inc. approved Change in Control Bonus Payment Agreements for its chief executive, financial, operating, and scientific and development officers. The agreements provide that the company will reimburse these executives for any excise taxes incurred under Section 4999 of the Internal Revenue Code in connection with a future change in control, potentially enhancing executive retention and aligning leadership incentives during strategic transactions.
The most recent analyst rating on (IRD) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, large losses, and accelerating cash burn). This is partially offset by strong technical positioning (price above key moving averages with positive MACD) and supportive corporate developments, including recent financing and pipeline milestone progress. Valuation is a secondary drag given negative earnings and no dividend support.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Opus Genetics, Inc. is a biotechnology company operating in the life sciences sector. The company focuses on developing genetic-based therapies and related scientific programs, led by a senior management team that includes its chief executive, financial, operating, and scientific and development officers.
Average Trading Volume: 948,853
Technical Sentiment Signal: Hold
Current Market Cap: $328M
See more insights into IRD stock on TipRanks’ Stock Analysis page.